Patient leaflet - Purevax RCP FeLV
B. PACKAGE LEAFLET
PACKAGE LEAFLET:
Purevax RCP FeLV lyophilisate and solvent for suspension for injection
-
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder :
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY
Manufacturer responsible for the batch release :
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint Priest
FRANCE
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RCP FeLV
Lyophilisate and solvent for suspension for injection.
-
3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per dose of 1 ml or 0.5 ml:
Lyophilisate:
Active substances:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)....................... > 109 CCID501
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens........... > 2.0 ELISA U.
Attenuated feline panleucopenia virus (PLI IV)............................................. > 103.5 CCID501
Excipient:
Gentamicin, at most..........................................................................................23 ^g
Solvent:
Active substance:
FeLV recombinant canarypox virus (vCP97).................................................. > 107.2 CCID501.
-
1 cell culture infective dose 50%.
Lyophilisate: homogeneous beige pellet.
Solvent: clear colourless liquid with presence of cell debris in suspension.
Onsets of immunity:
-
– Rhinotracheitis, calicivirus and panleucopenia components: 1 week after primary vaccination course.
-
– Feline leukaemia component : 2 weeks after primary vaccination course.
Duration of immunity:
-
– Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination.
-
– Feline Leukaemia component: 1 year after the last re-vaccination.
-
5. CONTRAINDICATIONS
None.
-
6. ADVERSE REACTIONS
Transient apathy and anorexia as well as hyperthermia (lasting usually for 1 or 2 days) were commonly observed during safety and field studies. A local reaction (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most was commonly observed during safety and field studies.
A hypersensitivity reaction has been observed uncommonly in field studies,, which may require appropriate symptomatic treatment
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals treated in 100 animals)
-
– uncommon (more than 1 but less than 10 animals treated in 1,000 animals)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
-
7. TARGET SPECIES
Cats
-
8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Subcutaneous route.
After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen) inject one dose of vaccine according to the following vaccination scheme:
Primary vaccination course:
-
– first injection: from 8 weeks of age;
-
– second injection: 3 to 4 weeks later.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Revaccination:
-
– the first revaccination must be carried out for all components one year after the primary vaccination course.
Subsequent revaccinations:
-
– Feline leukaemia component: every year.
-
– Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.
-
9. ADVICE ON CORRECT ADMINISTRATION
Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation. Visual appearance after reconstitution: slightly yellow suspension with presence of cell debris in suspension.
-
10. WITHDRAWAL PERIOD(S)
Not applicable.
-
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.
Do not use this veterinary medicinal product after the expiry date, which is stated on the label after EXP Shelf life after reconstitution according to directions: use immediately.
-
12. SPECIAL WARNING(S)
Special warnings for each target species:
Vaccinate healthy animals only.
Special precautions for use in animals :
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Vaccination of FeLV positive cats is of no benefit.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Pregnancy and lactation:
Do not use during the whole pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction:
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Overdose (symptoms, emergency procedures, antidotes) :
No effect other than those already mentioned in section on “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
Incompatibilities :
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product.
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency
-
15. OTHER INFORMATION